AnodyneWiki

Agomelatine

Agomelatine
Agomelatine
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass243.30 g/mol [1]
Solubility~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSO [1]
Predicted LogP2.7 [1]
Structural Identifiers
[]
Molecular formulaC15H17NO2
IUPAC nameN-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
SMILESCC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC
InChIInChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
InChIKeyYJYPHIXNFHFHND-UHFFFAOYSA-N
CAS number138112-76-2
UNII137R1N49AD
PubChem CID82148
Pharmacokinetics[]
Elimination half-life1–2 hours
MetabolismLiver (90% CYP1A2 and 10% CYP2C9)
ExcretionKidney (80%, mostly as metabolites)
Routes of administrationBy mouth
Dependence liabilityLow[3]

Agomelatine (also known as Thymanax, Valdoxan, S-20098, Agomelatina, Ago-178, S 20098, N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide, agomelatinum, Ago178 or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide) is a substance of the phenethylamine class.

Chemistry

 []

Agomelatine is achiral.

Agomelatine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors. [1]

Medical side effects []

57 side effects listed on drug labels in (agomelatine).

  • Eczema
  • Paraesthesia
  • Pruritus
  • Urticaria
  • Vision blurred
  • Hepatitis
  • Rash erythematous
  • Abdominal pain
  • Gastrointestinal pain
  • Aggression
  • Angioedema
  • Anxiety
  • Back pain
  • Mental disorder
  • Infection
  • Connective tissue disorder
  • Constipation
  • Depression
  • Diarrhoea
  • Dizziness
  • Dyspepsia
  • Eye disorder
  • Asthenia
  • Fatigue
  • Gastrointestinal disorder
  • Hallucination
  • Headache
  • Hyperhidrosis
  • Influenza
  • Irritability
  • Jaundice
  • Nasopharyngitis
  • Nausea
  • Nervous system disorder
  • Nightmare
  • Restless legs syndrome
  • Tinnitus
  • Tremor
  • Vertigo
  • Vomiting
  • Weight increased
  • Weight decreased
  • Dry mouth
  • Hepatic failure
  • Agitation
  • Migraine
  • Blood alkaline phosphatase increased
  • Skin disorder
  • Abnormal dreams
  • Hypomania
  • Hepatobiliary disease
  • Mania
  • Suicidal ideation
  • Face oedema
  • Infestation
  • Insomnia
  • Somnolence

Indications

  • Major depression

 []

  • Australia: Agomelatine is a Schedule 4.[4]
  • Brazil: Agomelatine is a C1.[5]
  • United Kingdom: Agomelatine is Prescription only.[6]
  • European Union: Agomelatine is Prescription only.[7][8]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 82148, Agomelatine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/82148
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Agomelatine. UNII: 137R1N49AD. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/137R1N49AD
  3. Kim HK, Yang KI. Melatonin and melatonergic drugs in sleep disorders. Translational and Clinical Pharmacology. December 2022; 30(4):163–171. PMID 36632077. https://doi.org/10.12793/tcp.2022.30.e21
  4. Valdoxan Product Information. TGA eBusiness Services. 2013-09-23. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3
  5. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-04-04. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  6. Valdoxan 25 mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 13 July 2020. https://www.medicines.org.uk/emc/product/6564/smpc
  7. Thymanax EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax
  8. Valdoxan EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 19:00:43
drugspromissing (no DrugsPRO reagent data)2026-11-20 19:00:39
erowidmissing (no Erowid substance of that name)2026-11-20 19:00:39
gsrsok2026-11-20 19:00:39
hmdbmissing (hmdb.ca refused automated access to HMDB0015636)2026-11-20 19:00:39
keggok2026-11-20 19:00:40
pubchemok2026-11-20 19:00:38
redditmissing (no r/tripreports posts mention it)2026-11-20 19:00:39
siderok2026-11-20 19:00:39
structureok2026-11-20 19:00:39
wikipediaok2026-11-20 19:00:39